Mode
Text Size
Log in / Sign up
N/A N=70 Other

Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation

Healthy

Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® Adt) — 1.84 % of oxygen saturated hemoglobin

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Philips FAST SpO2 with Masimo Pulse Oximetry Sensors (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Masimo Corporation
Primary completion
Jan 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® Adt)
1.84
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® Adt CS)
1.9
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® YI)
2.01
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® DBI)
1.99
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (LNCS® Adtx)
2.84
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® TC-I)
3.12
PRIMARY
Oxygen Saturation Performance of Philips FAST SpO₂ With Masimo Pulse Oximeter Sensor (RD SET® DCI)
3.85

Summary

Validate the performance of Philips FAST SpO2 with Masimo Pulse Oximetry Sensors in determining functional arterial oxygen saturation (SpO2) using arterial saturation (SaO2) as a reference in the range of 70-100% in subjects of varying skin pigmentation.

Eligibility Criteria

Inclusion Criteria (Eligible Subjects):

  • Subject is 18 to 50 years of age.
  • Subject weighs a minimum of 110 lbs.
  • Baseline heart rate ≥ 45 bpm and ≤ 90 bpm.
  • Blood Pressure: Systolic BP ≤ 140 mmHg and ≥ 90 mmHg, Diastolic BP ≤ 90 mmHg and ≥ 50 mmHg, and if systolic BP is lower than 100 mmHg and/or diastolic BP is lower than 60 mmHg, subject passes an orthostatic blood pressure test.
  • Hemoglobin value ≥ 11 g/dL.
  • CO value ≤ 3.0% FCOHb.
  • Subject can read and communicate in English and understands the study and the risks involved.

Exclusion Criteria (Ineligible Subjects) (* = per clinician discretion):

  • Subject is pregnant or breastfeeding.
  • Subject has a BMI > 35.
  • Subject has a history of fainting (vasovagal syncope), blacking out or losing consciousness during or after a blood draw, or has a fear of blood draws.
  • Subject has open wounds, inflamed tattoos, or piercings, and/or has any visible healing wounds that a medical professional determines may place them at an increased risk for participation. *
  • Subject has finger deformities, nail deformities, nail polish, and/or gel/acrylic that can interfere with study device placement. *
  • Subject has known drug or alcohol abuse.
  • Subject uses recreational drugs. *
  • Subject experiences frequent or severe headaches and/or migraine headaches, migraine auras, altitude sickness, and/or headaches accompanied by visual changes or sensitivity to light or sound.
  • Subject has experienced a concussion or head injury with loss of consciousness within the past 12 months.
  • Subject has any history of a stroke, myocardial infarction (heart attack), and/or seizures.
  • Subject has any chronic bleeding disorder (e.g., hemophilia).
  • Subject has taken anticoagulant medication within the past 30 days (excluding nonsteroidal anti-inflammatory drugs (NSAIDs)).
  • Subject has donated blood within the past 4 weeks.
  • Subject has any cardiac dysrhythmia (e.g., atrial fibrillation) and has not received clearance from their physician to participate.
  • Subject has a known neurological and/or psychiatric disorder (e.g., schizophrenia, bipolar disorder, Multiple Sclerosis, Huntington's disease) that interferes with the subject's level of consciousness. *
  • Subject has taken opioid pain medication 24 hours before the study.
  • Subject has any infectious disease (e.g., Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles). *
  • Subject is taking medications known to treat any type of infectious disease.
  • Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome.
  • Subject has had invasive surgery within the past year, including but not limited to major dental surgery, appendectomy, plastic surgery, jaw surgery, major ENT surgery, major abdominal and/or pelvic surgery, heart surgery, or thoracic surgery. *
  • Subject has symptoms of congestion, head cold, or other illnesses.
  • Subject has been in a severe car accident(s) or a similar type of accident(s) requiring hospitalization within the past 12 months.
  • Subject has any cancer or history of cancer (not including skin cancer). *
  • Subject has chronic unresolved asthma, lung disease (including COPD) and/or respiratory disease.
  • Subject is allergic to lidocaine, chlorhexidine, latex, adhesives, or plastic.
  • Subject has a heart condition, insulin-dependent diabetes, uncontrolled hypertension, or hypercholesterolemia.
  • Subject delivered vaginally, had a pregnancy terminated, had a miscarriage with hospitalization, or had a C-section within the past 6 months.
  • Subject intends on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle, tennis), exercise (e.g., working out, riding a bike, riding a skateboard), or any activity that will put additional stress on the wrist within 24 hours following a study that involves an arterial line.
  • Difficulty inserting an intravenous line in the subject's hand or arm and/or an arterial line in the radial artery of the subject's wrist.
  • Subje
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06148623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search